Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

´ã³¶ ¹× °£¿Ü´ãµµ°è ¾Ç¼ºÁ¾¾çÀÇ ¹æ»ç¼±Ä¡·á°á°ú The Role of Radiotherapy for Carcinomas of the Gall Bladder and Extrahepatic Biliary Duct : Retrospective Analysis

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 1998³â 16±Ç 1È£ p.43 ~ 50
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤ÇöÁÖ/Hyeon Ju Jeong ÀÌÇöÁÖ/¾ç±¤¸ð/¼­Çö¼÷/±è¿¹Èñ/±è¼º·Ï/±èÈ«¿ë/Hyun Ju Lee/Kwang Mo Yang/Hyun Suk Suh/Re Hwe Kim/Sung Rok Kim/Hong RyonB Kim

Abstract

¹è °æ :´ã³¶ ¹× °£¿Ü ´ãµµ°è ¾Ç¼ºÁ¾¾çÀÇ 5³â »ýÁ¸À²Àº 10% ÀÌÇÏ·Î ºñ±³Àû ¿¹ÈÄ°¡ ºÒ·®ÇÑ
°ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ÀÌ·¯ÇÑ Áúȯ¿¡¼­ ¹æ»ç¼±Ä¡·á°¡ Áõ»ó ¿ÏÈ­ ¹× Àüü »ýÁ¸À²À» Çâ»ó½ÃÅ°
´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ¾î, º»¿øÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÈÄÇâÀû ºÐ¼®À» ½ÃÇàÇÏ¿©, ¹æ»ç¼±Ä¡·áÀÇ ¿ª
ÇÒÀ» ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.
¹æ ¹ý : 1984³â 2¿ùºÎÅÍ 1995³â 11¿ù±îÁö ÀÎÁ¦´ëÇб³ ºÎ¼Ó ¹éº´¿ø ¹æ»ç¼±Á¾¾çÇаú¿¡¼­ ´ã
³¶ ¹× °£¿Ü ´ãµµ°è ¾Ç¼ºÁ¾¾çÀ¸·Î ¿ÏÄ¡ ¸ñÀûÀÇ ¹æ»ç¼± Ä¡·á¸¦ ¹ÞÀº 43¸íÀÇ È¯ÀÚÁß 3000cGy
ÀÌÇÏÀÇ ¹æ»ç¼±·®À» Á¶»ç¹ÞÀº 10¸íÀ» Á¦¿ÜÇÑ ÃÑ 33¸íÀÇ È¯ÀÚ(´ã³¶ ¾Ç¼º Á¾¾çÀº 21¸í, °£¿Ü
´ãµµ°è ¾Ç¼ºÁ¾¾ç 12¸í)¸¦ ´ë»óÀ¸·Î ÇÏ¿´´Ù. ³²³à ºñ´Â Àüü 11¸í´ë 22¸í(´ã³¶ ¾Ç¼ºÁ¾¾ç
4:17, °£¿Ü ´ãµµ°è ¾Ç¼ºÁ¾¾ç 7:5)À̾ú°í, ¿¬·ÉºÐÆ÷´Â 35-77¼¼(Áß¾Ó°ª 61¼¼)À̾ú´Ù. º´±âº°·Î´Â
¥³±â°¡ 19¸íÀ¸·Î °¡Àå ¸¹¾ÒÀ¸¸ç, Àç¹ßÈÄ ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº °æ¿ì°¡ 3¸í Æ÷ÇԵǾú´Ù. ¹æ»ç¼±
Ä¡·á´Â 4MV ¼±Çü°¡¼Ó±â¸¦ »ç¿ëÇÏ¿© ÃÑ 31.44-54.87Gy(Áß¾Ó°ª 44.25Gy)°¡ Á¶»çµÇ¾ú°í, 3¸í
ÀÇ È¯ÀÚ¿¡¼­´Â ü¿ÜÁ¶»ç ÀüÈÄ·Î ±ÙÁ¢Ä¡·á°¡ Ãß°¡µÇ¾ú´Ù. ¹æ»ç¼±Á¶»ç ´Üµ¶Ä¡·á´Â 6¸í, ¼ö¼ú
ÈÄ ¹æ»ç¼± Ä¡·á´Â 27¸í¿¡¼­ ½ÃÇàµÇ¾ú°í, ÀÌ Áß 16¸í¸¸ÀÌ ±ÙÄ¡ÀûÀýÁ¦¼úÀ» ½ÃÇà¹Þ¾Ò´Ù. Ç×¾ÏÈ­
Çпä¹ýÀº 17¸í¿¡¼­ º´ÇàµÇ¾úÀ¸¸ç ÀÌÁß 11¸íÀÌ Mitomycin+5-FU+LeucovorinÀ» »ç¿ëÇÏ¿´´Ù.
°á °ú : ÃÑ ÃßÀû°üÂû ±â°£Àº 2-97°³¿ù(Áß¾Ó°ª 8.5°³¿ù)À̾ú´Ù Àüü ȯÀÚÀÇ 2³â »ýÁ¸À²Àº
29.9 %, 5³â »ýÁ¸À²Àº 13.3%·Î ³ªÅ¸³µ´Ù. Áúȯº°·Î´Â ´ã³¶ÀÇ °æ¿ì 2³â »ýÁ¸À²ÀÌ 34.5%, °£
¿Ü´ãµµ°è ¾Ç¼ºÁ¾¾çÀº 27.8%À̾ú´Ù. ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇà¹ÞÀº ȯÀÚµéÀÇ 2³â »ýÁ¸À²Àº
30.1%À̸ç, ÀÌ Áß ±ÙÄ¡Àû ÀýÁ¦¼úÀ» ½ÃÇà¹ÞÀº 16¸íÀÇ 2³â »ýÁ¸À²Àº 43.8%·Î, ºÎºÐÀýÁ¦ ¹× ¿ì
ȸ¼ö¼úÈÄ ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇà¹ÞÀº 17¸íÀÇ 20.7%º¸´Ù ³ô°Ô ³ªÅ¸³µÀ¸³ª Åë°èÀû À¯ÀǼºÀº ¾ø¾ú
´Ù(p>0.05). º´±âº°·Î´Â 1, ¥±±âÀÇ 2 ³â »ýÁ¸À²ÀÌ 56.6%, ¥², ¥³±â´Â 23.6%·Î Åë°èÇÐÀûÀ¸·Î
À¯ÀÇÇÑ Â÷À̸¦ ³ªÅ¸³»¾ú´Ù(p<0.05). ECOG¿¡ ÀÇÇÑ ÀÓ»ó¼öÇà´É·ÂÁ¤µµ¿¡ µû¸¥ 2³â »ýÁ¸À²Àº 2
±Þ°ú 3±ÞÀÌ °¢°¢ 41.9%, 16.7%·Î Åë°èÇÐÀûÀ¸·Î À¯ÀÇÇÑ Â÷À̸¦ ³ªÅ¸³»¾ú´Ù(p<0.05). Ç×¾ÏÈ­
Çпä¹ýÀ» º´ÇàÇÑ ±ºÀÇ 2³â »ýÁ¸À²Àº 40.5%·Î Ç×¾ÏÈ­Çпä¹ýÀ» º´ÇàÇÏÁö ¾ÊÀº ±ºÀÇ 22.6% º¸
´Ù ºñ±³Àû ³ô°Ô ³ªÅ¸³µÀ¸³ª Åë°èÀû À¯ÀǼºÀº ¾ø¾ú´Ù(p>0.05).
°á ·Ð : º» ¿¬±¸°á°ú Àüü ȯÀÚÀÇ 2³â »ýÁ¸À²°ú 5³â »ýÁ¸À²Àº 29.9%¿Í 13.3%·Î ³ªÅ¸³µÀ¸
¸ç, º´±â°¡ ³·°í, ÀÓ»ó¼öÇà´É·ÂÀÌ ³ôÀ»¼ö·Ï »ýÁ¸À²ÀÌ Çâ»óµÊÀ» ¾Ë ¼ö ÀÖ¾ú´Ù. ¶ÇÇÑ ±ÙÄ¡Àû
ÀýÁ¦¼úÈÄ ¹æ»ç¼± Ä¡·á¸¦ ¹ÞÀº ȯÀÚ¿Í Ç×¾ÏÈ­Çпä¹ýÀ» º´ÇàÇÑ ±ºÀÇ Ä¡·á¼ºÀûÀÌ ºñ±³Àû ³ôÀº
°ÍÀ¸·Î º¼ ¶§, ´ã³¶ ¹× °£¿Ü ´ãµµ°è ¾Ç¼ºÁ¾¾çȯÀÚÁß ÀϺο¡¼­ Àû±ØÀûÀÎ º´ÇÕÄ¡·á¿ä¹ýÀÌ »ý
Á¸À²ÀÇ Çâ»ó¿¡ µµ¿òÀ» ÁÙ °ÍÀ¸·Î ±â´ëµÈ´Ù.

Purpose : Carcinomas arising in the gall bladder(GB) or extrahepatic biliary ducts are
uncommon and generally have a poor prognosis. The overall 5-year survival rates are
less than 10%. Early experiences with the external radiation therapy demonstrated a
good Palliation with occasional long-term survival. The present report describes our
experience over the past decade with irradiation of primary carcinomas of the gallbladder
and extrahepatic biliary duct
Materials and Methods : From Feb. 1984 to Nov. 1995, thirty-three patients with
carcinoma of the GB and extrahepatic biliary duct were treated with external beam
radiotherapy with curative intent at our institution. All patients were treated with 4-MV
linear accelerator and radiation dose ranged from 31.440y to 54.870y(median 44.250y), and
three patients received additional intraluminal brachytherapy(range, 25Gy to 30Gy).
Twenty-seven patients received postoperative radiation. Among 27 patients, Sixteen
patients underwent radical operation with curative aim and the rest of the patients either
had bypass surgery or biopsy alone. In seventeen patients, adjuvant chemotherapy was
used and eleven Patients were treated with 5-FU, mitomycin and leucovorin.
Results : Median follow up period was 8.5 months(range 2-97 months). The overall
2-year and 5-year survival rates in all patients were 29.9% and 13.3 % respectively. In
patients with GB and extrahepatic biliary duct carcinomas, the 2-year survival rates
were 34.5% and 27.8% respectively. Patients who underwent radical operation showed
better 2-year survival rates than those who underwent Palliative operation(43.8% vs.
20.7%), albeit statistically insignificant(¥â>0.05). The 2-rear survival rates in Stage ¥°
and ¥± were higher than in Stage ¥² and ¥³ with statistical significance(p<0.05).
Patients with good performance status in the beginning showed significantly better
survival rates than those with worse status(p<0.05). The 2-year survival rates in
combined chemotherapy group and radiation group were 40.5% and 22.6% respectively.
There was no statistical differences in two grouts (p>0.05).
Conclusion : The survival of patients with relatively lower stage and/or initial good
performance was significantly superior to that of others. We found an statistically
insignificant trend toward better survival in patients with radical operation and/or
chemotherapy. More radical treatment strategies, such as total resection with intensive
radiation and/or chemotherapy may offer a better chance for cure in selective Patients
with carcinoma of gall bladder and extrahepatic biliary ducts.

Å°¿öµå

Carcinoma of grill bladder; Carcinoma of extrahepatic biliary duct; Radiotherapy;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS